Dysmenorrhea
Clinical Snapshot
Dysmenorrhea is pain — typically crampy, lower mid-abdominal and/or pelvic pain — occurring with menstruation. Primary dysmenorrhea occurs without identifiable pelvic pathology, in ovulatory cycles, and results from excess endometrial prostaglandin production driving painful myometrial contractions and transient uterine ischemia; onset is usually within 2 years of menarche, it is most severe in young nulliparous patients, and it tends to improve with age. Secondary dysmenorrhea results from an identifiable underlying pelvic pathology — most often endometriosis, adenomyosis, or a structural/obstructive uterine abnormality — and its age of onset is variable.[1] Dysmenorrhea is common and frequently undertreated despite effective, low-cost therapy being available. A therapeutic trial of an NSAID and/or hormonal contraception should be started on the strength of a typical history, without waiting for a pelvic examination or imaging, whenever the presentation is a classic primary-dysmenorrhea pattern.
Recognize the Condition
Typical pattern of primary dysmenorrhea
Pain classically starts within several hours before the onset of menstrual bleeding, up to a few hours after the start of menses, and lasts a maximum of about 3 days. It is described as crampy, cyclic, lower mid-abdominal and/or pelvic pain that may radiate to the back or thighs.
Because the pain is driven by systemic prostaglandin release, it is frequently accompanied by other prostaglandin-excess symptoms: nausea, vomiting, diarrhea, backache, thigh pain, headache, and dizziness.[1]
Primary vs. secondary dysmenorrhea
Primary dysmenorrhea
Occurs in ovulatory cycles with no identifiable pelvic pathology. Onset is usually within 2 years of menarche, most severe in young nulliparous patients, and tends to improve with age. Pain is relieved or clearly ameliorated by an adequate empiric trial of NSAIDs and/or ovulation-suppressing hormonal therapy.
Secondary dysmenorrhea
Results from an underlying pelvic pathology — endometriosis, adenomyosis, a submucous uterine fibroid, an endometrial polyp, an intrauterine device, pelvic inflammatory disease, a vaginal septum, an imperforate hymen, a congenital Müllerian malformation, or post-endometrial-ablation syndrome. Age of onset is variable and can follow a period of normal, pain-free cycles. Diagnostic clues include pain onset premenstrually, pain lasting throughout the menses, dyspareunia, abnormal uterine bleeding, or infertility. Only partial symptomatic improvement is typical with NSAIDs alone.
Risk Factors
- Menarche before age 12.
- Increased duration and volume of menstrual flow.
- Smoking or passive smoke exposure — an independent risk factor for dysmenorrhea.
- Low body mass index.
- Family history of dysmenorrhea.
- Nulliparity.
- Mood disorders.
- Prior sexual abuse.
- Poor social support.
Red Flags & Refer
Most menstrual cramping is primary dysmenorrhea and responds to a correctly-timed empiric trial. Escalate or refer for any of the following:[1]
- Pain that does not respond to an adequate, correctly-timed trial of an NSAID and/or hormonal therapy.
- Pain occurring outside the expected primary-dysmenorrhea pattern — onset more than 2 years after menarche, new onset after age 30 with no prior history of dysmenorrhea, pain that begins premenstrually or persists throughout the cycle, or pain lasting longer than about 3 days.
- New or worsening pain in a patient whose dysmenorrhea was previously well-controlled on the same regimen.
- Dyspareunia, infertility, or abnormal uterine bleeding accompanying the pain — all point toward secondary dysmenorrhea rather than primary.
- Signs suggesting an acute gynecologic or surgical emergency — fever, peritoneal signs, a palpable pelvic mass, or hemodynamic instability — need same-day assessment rather than a scheduled trial of therapy.
- A pelvic examination that cannot be adequately performed (e.g., significant obesity, or the patient is unable or unwilling to be examined) when secondary dysmenorrhea is suspected — refer for imaging rather than leaving this unresolved.
Assessment & Diagnosis
History
Take a thorough history of the pain's severity, timing, duration, and character, along with aggravating and relieving factors. The pain of primary dysmenorrhea typically starts within several hours before the onset of bleeding up to a few hours after the start of menses, lasts a maximum of 3 days, and is described as crampy, lower mid-abdominal and/or pelvic pain, often with nausea, vomiting, diarrhea, backache, thigh pain, headache, or dizziness.[1]
Physical examination
Examine the abdomen and pelvis to look for signs of secondary dysmenorrhea. In a patient who has never been sexually active, an abdominal examination and inspection of the external genitalia are sufficient. In a sexually active patient, add a single-digit vaginal examination, carefully palpating each pelvic structure to isolate tenderness, masses, or nodules. Suspect secondary dysmenorrhea specifically in a patient over age 30 with no prior history of dysmenorrhea, and in any patient refractory to first-line medical therapy.
Investigations
No laboratory test is required or helpful for diagnosing primary dysmenorrhea. In the absence of an abnormal history or examination finding, diagnostic imaging is unlikely to help and may mislead if it turns up a noncontributory incidental finding.
Reserve diagnostic laparoscopy for refractory dysmenorrhea in which endometriosis is suspected — this is a specialist-directed investigation, not a routine primary-care step.[1]
Primary vs. secondary dysmenorrhea: distinguishing features
| Feature | Primary dysmenorrhea | Secondary dysmenorrhea |
|---|---|---|
| Pelvic pathology | None identifiable | Present — endometriosis, adenomyosis, submucous fibroid, endometrial polyp, IUD, pelvic inflammatory disease, vaginal septum, imperforate hymen, Müllerian anomaly, post-ablation syndrome |
| Cycle relationship | Occurs in ovulatory cycles | Variable |
| Typical age pattern | Onset within 2 years of menarche; most severe in young, nulliparous patients; tends to improve with age | Onset age is variable and can follow a period of normal, pain-free cycles |
| Pain timing | Begins shortly before to shortly after the start of bleeding; resolves within about 3 days | May begin premenstrually and/or persist throughout the menses |
| Mechanism | Myometrial contractions driven by endometrial prostaglandin production | Depends on the underlying pathology |
| Associated features | Nausea, vomiting, diarrhea, backache, thigh pain, headache, dizziness (prostaglandin-excess symptoms) | Dyspareunia, infertility, and/or abnormal uterine bleeding are additional clues |
| Response to empiric therapy | Relieved or clearly ameliorated by an adequate NSAID and/or hormonal contraception trial | Only partial improvement typical with NSAIDs alone |
| Smoking association | More common in people who smoke | Not a specific association |
Treatment Targets
- Decrease or abolish menstrual pain and the associated prostaglandin-excess symptoms.
- Restore normal activity, attendance, and quality of life during menses.
- Avoid unnecessarily delaying symptomatic treatment while a definitive diagnosis is pursued.
- When contraception is also desired, select a therapy that accomplishes both goals at once.
- For secondary dysmenorrhea, identify and direct treatment at the specific underlying cause.
Choose Initial Treatment
1st line Start an NSAID — ibuprofen, naproxen, or mefenamic acid — scheduled (not PRN), starting immediately at the onset of symptoms or menses and continued on a regular schedule for 2–3 days; an initial loading dose speeds relief.[2]
1st line, equally preferred when contraception is also desired: start a combined hormonal contraceptive (pill, patch, or ring) — continuous or extended-cycle regimens are generally preferable to cyclic regimens for dysmenorrhea specifically.
2nd line — use when an adequate 3–6 month trial of either an NSAID or a combined hormonal contraceptive alone has not controlled symptoms: combine an NSAID with a combined hormonal contraceptive before proceeding to further investigation.
Special situation — estrogen contraindicated, or age over 35 and a current smoker: a progestin-only option (the levonorgestrel intrauterine system, depot medroxyprogesterone acetate, or the etonogestrel implant) is a reasonable hormonal alternative to a combined hormonal contraceptive.
Avoid using acetaminophen as first-line therapy — it produces only minimal analgesic effect in dysmenorrhea and gives inferior pain relief compared with an NSAID; reserve it for a patient with a genuine NSAID contraindication.
Continue or start hormonal contraception while investigations for suspected secondary dysmenorrhea are pending — hormonal contraception is itself an effective treatment for the pain of endometriosis and adenomyosis, so starting it does not need to wait for a completed workup.[1]
Full contraceptive method selection, counselling, and safety screening (migraine with aura, venous thromboembolism risk factors, and similar) is beyond this chapter's scope — see current hormonal contraception prescribing guidance for that assessment.
Non-Pharmacologic Treatment
- Heat therapy (a heating pad or heat patch applied to the lower abdomen) achieves analgesic efficacy comparable to an NSAID with substantially fewer adverse effects, though the certainty of the pain-reduction evidence is still rated low to moderate — a reasonable option, particularly for a patient who cannot or prefers not to use conventional pharmacotherapy.[3]
- Regular exercise may provide pain relief. Both low-intensity (e.g., yoga, stretching) and high-intensity (e.g., aerobic training) exercise for 45–60 minutes, 3 times per week, have shown benefit; in most supporting studies, exercise was carried out throughout the month, including during menses.[4]
- High-frequency transcutaneous electrical nerve stimulation (TENS) reduces pain and reduces the need for additional pain medication compared with placebo, based on moderate-quality evidence.[5]
- Smoking cessation — smoking is an independent risk factor for dysmenorrhea; support cessation as part of ongoing management.
- Natural health products — evidence quality is generally low across this category, but several may provide benefit: fenugreek, ginger, valerian, zataria, zinc sulphate, fish oil, fish oil plus vitamin B1, and vitamin B1 alone.[6] Ginger has the most supportive data specifically: 750–2000 mg PO daily for 3–4 days, starting at the onset of the menstrual cycle.
- Surgical management (laparoscopic uterosacral ligament resection, presacral neurectomy, or hysterectomy with or without oophorectomy) is reserved for dysmenorrhea refractory to medical management, usually in the context of secondary dysmenorrhea.
- Current evidence for behavioural interventions and acupoint stimulation (acupressure or acupuncture) remains limited and does not support a specific recommendation over the measures above.
Special Populations
Pregnancy
Dysmenorrhea occurs with ovulatory menstrual cycles and does not apply during pregnancy. For a patient trying to conceive, avoid relying on an NSAID for cycle-related pain around the expected time of ovulation or implantation, and use acetaminophen instead if analgesia is needed; NSAIDs and combined hormonal contraceptives are not appropriate once pregnancy is confirmed or suspected.
Breastfeeding
Ibuprofen and naproxen are both considered compatible with breastfeeding at usual analgesic doses. Combined hormonal contraceptives are generally avoided in the first 6 weeks postpartum and used with caution while breastfeeding is being established thereafter; a progestin-only option (the LNG-IUS, DMPA, or the etonogestrel implant) is preferred if a breastfeeding patient needs hormonal management of dysmenorrhea.
Adolescents
NSAID and combined hormonal contraceptive therapy are both appropriate first-line options in adolescents, and treatment can be started on the strength of a typical history without requiring a pelvic examination first.[7] Consider a congenital Müllerian anomaly (e.g., an obstructive outflow abnormality) in an adolescent with severe dysmenorrhea dating from menarche, particularly if it is refractory to first-line therapy.
Adolescents 12-18 years using DMPA
Use DMPA with caution in this age group, since peak bone mass has not yet been reached; bone mineral density typically returns to baseline after discontinuation. Encourage adequate calcium (1200 mg elemental calcium daily from all sources, preferably dietary) and vitamin D (1000 units daily) while on DMPA.
Renal impairment
Avoid NSAIDs in severe renal impairment; use the lowest effective dose for the shortest duration, with caution, in milder renal impairment.
NSAID or ASA hypersensitivity
Celecoxib may be considered in a patient with NSAID hypersensitivity, including ASA-hypersensitivity, depending on the specific type of reaction — assess the reaction pattern before selecting an alternative agent, and avoid celecoxib specifically in a patient with a sulfonamide allergy.
Monitoring & Follow-Up
Reassess response after a therapeutic trial of 3-6 months with either an NSAID (regularly scheduled, starting before or at the onset of menstruation, continued 2-3 days) or a combined hormonal contraceptive — this duration is usually sufficient to judge effectiveness. At each follow-up, confirm the medication is actually being taken on a fixed schedule starting early enough in the cycle, not as a late PRN dose once pain is already severe. With regular NSAID use, ask about GI symptoms (dyspepsia, black stool) and reassess the ongoing need versus risk, particularly with continued long-term use. For a patient using DMPA, review bone-health counselling (calcium/vitamin D) and the trade-off of delayed return to fertility at each visit. If pain is not controlled at 3-6 months despite an adequate, correctly-taken trial, proceed to the Treatment Failure/Next Step sequence rather than simply repeating or increasing the same regimen.
Common Errors to Avoid
- Starting the NSAID only after pain is already severe, rather than scheduling it to begin at or just before the onset of symptoms or menses.
- Using PRN dosing instead of a regularly scheduled dose for the first 2-3 days of the cycle.
- Skipping the initial loading dose, which helps achieve faster symptom relief.
- Reaching for acetaminophen as a first-line agent — it is measurably less effective than an NSAID for dysmenorrhea.
- Assuming severe menstrual pain in a young patient is simply normal cramping and not offering treatment.
- Missing secondary dysmenorrhea in a patient over 30 with new-onset pain, or in any patient refractory to an adequate first-line trial.
- Ordering pelvic imaging routinely before a therapeutic trial when the history is a classic primary-dysmenorrhea pattern with a normal examination.
- Not asking whether the patient also wants contraception — a missed opportunity to select a combined hormonal contraceptive that treats both at once.
- Withholding hormonal contraception while investigations for suspected secondary dysmenorrhea are still pending, when it could be relieving symptoms in the meantime.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation. All NSAIDs listed are contraindicated in ASA hypersensitivity, active peptic ulcer disease or GI bleeding, significant renal impairment, and clotting disorders — confirm before selecting an agent. Select any drug name to open its complete Pharmasist Drug Database page.
NSAIDs — COX-2 inhibitor
An option for a patient at higher risk of GI adverse effects, or with NSAID/ASA hypersensitivity depending on the specific reaction type.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Celecoxib | Adults: 200 mg PO daily in 1 or 2 divided doses, with food | Very common: dyspepsia, nausea/vomiting. Common: nonspecific rash, pruritus, dizziness, headache. | SSRIs may increase GI bleeding risk in combination. Contraindicated with ASA hypersensitivity, active peptic ulcer disease/inflammatory bowel disease, existing renal disease, a clotting disorder, or sulfonamide allergy. | First line for dysmenorrhea. Begin at onset of symptoms or menses and continue on a fixed schedule for 2-3 days; a loading dose speeds relief. Adult dosing applies once a patient is menstruating — a separate pediatric regimen is not established for this indication. |
NSAIDs — propionic acid derivatives
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Ibuprofen | Adults, loading dose: 800 mg PO Adults, maintenance: 400 mg PO Q6H PRN with food Adults, maximum: 2400 mg/day | Very common: dyspepsia, nausea/vomiting. Common: nonspecific rash, pruritus, dizziness, headache. May be nephrotoxic — avoid in severe renal impairment. | SSRIs may increase GI bleeding risk in combination. Avoid combining with other NSAIDs or ASA. Contraindicated with ASA hypersensitivity, active peptic ulcer disease/GI bleeding, existing renal disease, or a clotting disorder. | First line for dysmenorrhea. Begin at onset of symptoms or menses and continue on a fixed schedule for 2-3 days; a loading dose speeds relief. Adult dosing applies once a patient is menstruating — a separate pediatric regimen is not established for this indication. Available without prescription. |
| Naproxen | Adults, loading dose: 500 mg PO Adults, maintenance: 250 mg PO Q6-8H, or 500 mg BID, with food Adults, maximum: 1250 mg/day | Very common: dyspepsia, nausea/vomiting. Common: nonspecific rash, pruritus, dizziness, headache. May be nephrotoxic — avoid in severe renal impairment. | SSRIs may increase GI bleeding risk in combination. Avoid combining with other NSAIDs or ASA. Contraindicated with ASA hypersensitivity, active peptic ulcer disease/GI bleeding, existing renal disease, or a clotting disorder. | First line for dysmenorrhea. Begin at onset of symptoms or menses and continue on a fixed schedule for 2-3 days; a loading dose speeds relief. Adult dosing applies once a patient is menstruating — a separate pediatric regimen is not established for this indication. |
| Naproxen sodium | Adults: 220-550 mg PO BID with food | Very common: dyspepsia, nausea/vomiting. Common: nonspecific rash, pruritus, dizziness, headache. May be nephrotoxic — avoid in severe renal impairment. | SSRIs may increase GI bleeding risk in combination. Avoid combining with other NSAIDs or ASA. Contraindicated with ASA hypersensitivity, active peptic ulcer disease/GI bleeding, existing renal disease, or a clotting disorder. | First line for dysmenorrhea. Begin at onset of symptoms or menses and continue on a fixed schedule for 2-3 days; a loading dose speeds relief. Adult dosing applies once a patient is menstruating — a separate pediatric regimen is not established for this indication. Naproxen sodium 220 mg tablets are available without prescription; this is the same molecule as naproxen, formulated as the sodium salt for faster absorption. |
| Ketoprofen | Adults: 50 mg PO TID with food | Very common: dyspepsia, nausea/vomiting. Common: nonspecific rash, pruritus, dizziness, headache. May be nephrotoxic — avoid in severe renal impairment. | SSRIs may increase GI bleeding risk in combination. Avoid combining with other NSAIDs or ASA. Contraindicated with ASA hypersensitivity, active peptic ulcer disease/GI bleeding, existing renal disease, or a clotting disorder. | First line for dysmenorrhea. Begin at onset of symptoms or menses and continue on a fixed schedule for 2-3 days; a loading dose speeds relief. Adult dosing applies once a patient is menstruating — a separate pediatric regimen is not established for this indication. |
NSAIDs — fenamates
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Mefenamic acid | Adults, loading dose: 500 mg PO Adults, maintenance: 250 mg PO Q6H with food | Very common: dyspepsia, nausea/vomiting. Common: nonspecific rash, pruritus, dizziness, headache. May be nephrotoxic — avoid in severe renal impairment. | SSRIs may increase GI bleeding risk in combination. Avoid combining with other NSAIDs or ASA. Contraindicated with ASA hypersensitivity, active peptic ulcer disease/GI bleeding, existing renal disease, or a clotting disorder. | First line for dysmenorrhea. Begin at onset of symptoms or menses and continue on a fixed schedule for 2-3 days; a loading dose speeds relief. Adult dosing applies once a patient is menstruating — a separate pediatric regimen is not established for this indication. |
NSAIDs — acetic acid derivatives
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Diclofenac potassium | Adults, loading dose: 100 mg PO Adults, maintenance: 50 mg PO Q6-8H PRN with food Adults, maximum: 200 mg on day 1, then 100 mg/day on days 2-7 | Very common: dyspepsia, nausea/vomiting. Common: nonspecific rash, pruritus, dizziness, headache. May be nephrotoxic — avoid in severe renal impairment. | SSRIs may increase GI bleeding risk in combination. Avoid combining with other NSAIDs or ASA. Contraindicated with ASA hypersensitivity, active peptic ulcer disease/GI bleeding, existing renal disease, or a clotting disorder. | First line for dysmenorrhea. Begin at onset of symptoms or menses and continue on a fixed schedule for 2-3 days; a loading dose speeds relief. Adult dosing applies once a patient is menstruating — a separate pediatric regimen is not established for this indication. Immediate-release (Voltaren Rapide) formulation, suited to short cyclic courses. |
Simple analgesic (NSAID alternative)
Reserve for a patient with a genuine NSAID contraindication — measurably less effective than an NSAID for dysmenorrhea.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Acetaminophen | Adults: 500-1000 mg PO Q6H PRN Adults, maximum: 4000 mg/day | Generally well tolerated at recommended doses; hepatotoxicity with overdose or chronic excessive use. | Increased hepatotoxicity risk with chronic alcohol use; caution with other acetaminophen-containing products (risk of unintentional overdose). | Demonstrates minimal analgesic effect in dysmenorrhea and gives inferior pain relief compared with an NSAID. |
Combined hormonal contraceptives
Inhibit ovulation, limiting endometrial growth and menstrual prostaglandin production. An ideal first-line choice when the patient also wants contraception. Continuous or extended-cycle regimens decrease the frequency of periods and the prevalence of pain and are generally preferable to cyclic regimens; this also ameliorates dysmenorrhea due to endometriosis or adenomyosis.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Combined oral contraceptive (e.g., levonorgestrel/ethinyl estradiol) | Cyclic regimen: 1 tablet PO daily for 21 days, then 7 hormone-free days Continuous/extended-cycle regimen (preferred for dysmenorrhea): 1 tablet PO daily on a continuous or extended schedule per product labeling | Breakthrough bleeding, breast tenderness, nausea, headache; rare venous thromboembolism. | Enzyme-inducing drugs (certain anticonvulsants, rifampin, St. John's wort) may reduce contraceptive efficacy. | Effective with both medium- and low-dose estrogen formulations (ethinyl estradiol 35 mcg or less). Full method-selection counselling is beyond this chapter's scope — see current hormonal contraception prescribing guidance. |
| Contraceptive patch | Dosing: 1 patch applied weekly for 3 weeks, then 1 patch-free week (or continuous per product labeling) | Breakthrough bleeding, breast tenderness, application-site reaction; rare venous thromboembolism. | Enzyme-inducing drugs may reduce contraceptive efficacy. | As effective as an oral combined contraceptive for dysmenorrhea. |
| Vaginal ring | Dosing: 1 ring inserted vaginally, worn continuously for 3 weeks, then removed for 1 week (or continuous per product labeling) | Breakthrough bleeding, vaginal irritation/discharge; rare venous thromboembolism. | Enzyme-inducing drugs may reduce contraceptive efficacy. | As effective as an oral combined contraceptive for dysmenorrhea. |
Progestin-only options
Effective for dysmenorrhea whether the cause is primary or secondary (e.g., adenomyosis, endometriosis); can be started while investigations for secondary dysmenorrhea are still pending.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Levonorgestrel intrauterine system (LNG-IUS) | Adults: 52 mg intrauterine system; duration of use per the specific product's approved labeling | Irregular spotting, especially in the first 3-6 months; amenorrhea over time; insertion-related cramping or pain; rare uterine perforation or expulsion. | None significant — minimal systemic absorption. | No Pharmasist Drug Database monograph currently exists for this device — do not link to the oral levonorgestrel emergency-contraception monograph, which is a different formulation and indication. Produces an atrophic, inactive endometrium and substantially reduces menstrual blood loss; ovulation is not suppressed in all patients. Good-quality evidence supports use in dysmenorrhea associated with adenomyosis or endometriosis specifically. |
| Depot medroxyprogesterone acetate (DMPA) | Adults, IM: 150 mg IM every 12-13 weeks Adults, SC: 104 mg SC every 12-13 weeks | Amenorrhea or irregular bleeding, weight gain, reversible bone mineral density loss, headache, mood changes. | None significant. | Consider when estrogen cannot be tolerated, or in a patient over 35 who currently smokes. Return to fertility may be delayed after discontinuation — discuss alternatives if pregnancy is desired soon. Also useful for secondary dysmenorrhea from endometriosis, adenomyosis, or a structural uterine abnormality. Counsel calcium 1200 mg/day and vitamin D 1000 units/day, particularly in adolescents 12-18 years who have not yet reached peak bone mass. |
| Etonogestrel implant | Adults: 68 mg single rod, inserted subdermally; replace per the approved duration of use | Irregular bleeding (most common reason for discontinuation), headache, weight change, acne, mood changes, insertion-site reaction. | Enzyme-inducing drugs (certain anticonvulsants, rifampin) may reduce effectiveness. | Single-rod subdermal implant. Decreases bleeding days per month, which may also benefit heavy menstrual bleeding and endometriosis-associated pain. |
Natural health products
Evidence quality is generally low across this category as a whole; ginger has the most supportive data.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Ginger | Adults: 750-2000 mg PO daily for 3-4 days, starting at the beginning of the menstrual cycle | GI upset (mild). | None well established. | May be comparable to NSAID treatment for pain relief; high-quality confirmatory trials are still needed. Other supplements proposed with low-quality evidence include fenugreek, valerian, zataria, zinc sulphate, fish oil, fish oil plus vitamin B1, and vitamin B1 alone. |
Adjuncts for refractory pain with chronic/neuropathic features
Consider alongside — not instead of — ongoing gynecologic management for a patient with poorly controlled dysmenorrhea and overlapping chronic pelvic pain.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Amitriptyline | Adults: 10-25 mg PO at bedtime, titrated as tolerated | Anticholinergic effects (dry mouth, constipation, urinary retention), sedation, orthostatic hypotension, QT prolongation at higher doses. | Avoid with MAOIs; additive sedation with other CNS depressants; caution with other QT-prolonging drugs. | |
| Gabapentin | Adults: 100-300 mg PO at bedtime, titrated as tolerated based on response | Somnolence, dizziness, peripheral edema, ataxia. | Additive CNS depression with opioids or other sedatives; antacids reduce absorption (separate dosing by 2 hours). |
Evidence note: Drug inventory, dosing, adverse effects, and comments reflect standard Canadian practice, cross-checked against the current SOGC guideline and current Cochrane evidence.[1]
References
- Guideline No. 345: Primary Dysmenorrhea — Journal of Obstetrics and Gynaecology Canada, Society of Obstetricians and Gynaecologists of Canada (Burnett M). J Obstet Gynaecol Can 2025;47(5):102840
- Nonsteroidal anti-inflammatory drugs for dysmenorrhoea — Cochrane Database of Systematic Reviews (Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M). Cochrane Database Syst Rev 2015;7:CD001751
- Heat therapy for primary dysmenorrhea: a systematic review and meta-analysis — Frontiers in Medicine (Yuan D, Liu Y, Chen Z, et al.). Front Med 2025;12:1730505
- Exercise for dysmenorrhoea — Cochrane Database of Systematic Reviews (Armour M, Ee CC, Naidoo D, et al.). Cochrane Database Syst Rev 2019;9:CD004142
- Transcutaneous electrical nerve stimulation (TENS) for pain control in women with primary dysmenorrhoea — Cochrane Database of Systematic Reviews (Han S, Park KS, Lee H, et al.). Cochrane Database Syst Rev 2024;7:CD013331
- Dietary supplements for dysmenorrhoea — Cochrane Database of Systematic Reviews (Pattanittum P, Kunyanone N, Brown J, et al.). Cochrane Database Syst Rev 2016;3:CD002124
- ACOG Committee Opinion No. 760: Dysmenorrhea and Endometriosis in the Adolescent — Obstetrics & Gynecology, American College of Obstetricians and Gynecologists Committee on Adolescent Health Care. Obstet Gynecol 2018;132(6):e249-e258
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.